On Wednesday, Shares of salesforce.com, inc. (NYSE:CRM), SUBTRACT -5.80% and closed at $68.42 in the last trading session. The last trading range of the stock ranges between $66.77 and $69.60. Salesforce (CRM), the Customer Success Platform and world’s #1 CRM company, today kicked off Dreamforce 2016 and introduced the next generation of its Customer Success Platform. With eight clouds that span sales, service, marketing, commerce, communities, analytics, IoT and app development, all on a single trusted cloud platform, Salesforce is transforming the relationships companies have with their customers. And today, the company is creating a new path forward for customers with breakthrough innovations such as Quip to supercharge productivity; Salesforce Einstein to make every customer interaction smarter; and advancements in the Salesforce1 Mobile App, Salesforce Platform and IoT Cloud.
“At Dreamforce, Salesforce is unveiling unprecedented innovation that is paving the path forward for our Customer Trailblazers,” said Alex Dayon, President and Chief Product Officer, Salesforce. “By delivering new levels of intelligence, speed, mobility, productivity and connectivity across the Salesforce Customer Success Platform, we’re empowering companies to get closer to their customers and achieve entirely new levels of success.”
Exelixis, Inc. (NASDAQ:EXEL), jumped 5.47% and closed at $13.12 in the last trading session. The last trading range of the stock ranges between $12.21 and $13.17. The company’s Market capitalization is $2.96 Billion with the total Outstanding Shares of 230.33 Million. Exelixis, Inc. (EXEL) recently declared that the company and its partner Ipsen will jointly host a live shareholder and media briefing at the European Society for Medical Oncology (ESMO) 2016 Congress. The event will be held on Monday, October 10, 2016, with the program starting at 19:00 CEST (local Copenhagen time) / 1:00 p.m. EDT / 10:00 a.m. PDT following on-site registration starting at 18:30 CEST.
During the briefing, Exelixis and Ipsen administration and invited guests will discuss and provide context for clinical data for cabozantinib presented at the ESMO 2016 Congress. Key topics will include CABOSUN, the randomized phase 2 trial of cabozantinib contrast with sunitinib in patients with formerly untreated advanced renal cell carcinoma, which will be the subject of a late-breaking oral presentation during ESMO’s Presidential Symposium 3 earlier in the day. Presenters will also review data from the ongoing phase 1b trial evaluating the combination of cabozantinib and nivolumab in patients with genitourinary tumors.
Sprouts Farmers Market Inc (NASDAQ:SFM), LOST -0.91% and closed at $20.58 in the last trading session. The last trading range of the stock ranges between $20.54 and $20.97. During the 52-week trading session the minimum price at which share price traded, registered at$18.70 and reached to max level of $30.00. Sprouts Farmers Market, Inc., together with its auxiliaries, operates as a retailer of fresh, natural, and organic food in the United States. The companys retail stores offer fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items, beer and wine, and dairy alternatives.